Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Department of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Leuk Lymphoma. 2024 Jan;65(1):26-36. doi: 10.1080/10428194.2023.2264429. Epub 2024 Jan 10.
The protooncogene plays a critical role in many cellular processes. translocations are recurrent in large B-cell lymphomas (LBCLs) where they exhibit a negative effect on survival. Gain of copies is also frequently identified; however, there is no consensus on the frequency and prognostic significance of copy gains. We collected FISH data for with reflex testing for and and IHC results at diagnosis for a cohort of 396 and transformed LBCL cases and compared progression-free (PFS) and overall survival (OS) to determine the prognostic impact of extra copies. The prevalence of cases with copy number gain was 20.9%. PFS was shorter for patients with ≥5 copies compared to controls ( = 0.0005, HR = 2.25). gain trended towards worse OS; patients with ≥7 copies had worse OS ( = 0.013), similar to patients with translocations. We propose that gain represents a dose-dependent prognostic factor for LBCLs.
原癌基因在许多细胞过程中起着关键作用。易位在大 B 细胞淋巴瘤（LBCL）中频繁发生，它们对生存有负面影响。也经常发现 拷贝数的增加；然而，对于 拷贝数增加的频率和预后意义尚无共识。我们收集了 396 例弥漫性大 B 细胞淋巴瘤和转化性大 B 细胞淋巴瘤病例的 FISH 数据，并进行了 和 的反射性检测以及诊断时的 IHC 结果，以比较无进展生存期（PFS）和总生存期（OS），从而确定额外 拷贝数的预后影响。具有 拷贝数增加的病例的患病率为 20.9%。与对照组相比，≥5 拷贝的患者 PFS 更短（=0.0005，HR=2.25）。 获得与 OS 更差呈趋势相关；≥7 拷贝的患者 OS 更差（=0.013），与 易位的患者相似。我们提出， 获得代表弥漫性大 B 细胞淋巴瘤的一种剂量依赖性预后因素。
